Figure 3 | British Journal of Cancer

Figure 3

From: Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis

Figure 3

Progression-free survival analysis in exon 19 deletion tumours. (A) PFS analysis in exon 19 deletion tumours receiving reversible and irreversible TKIs. Pooled analysis showed significant PFS benefits in both reversible and irreversible TKIs. (B) PFS analysis in exon 19 deletion tumours receiving cisplatin- and carboplatin-based chemotherapy. Pooled analysis showed significant PFS benefit towards TKI treatment in both cisplatin- and carboplatin-based chemotherapy. Squares indicate study-specific HRs (size of the square reflects the study-specific statistical weight); horizontal lines indicate 95% CI; diamond indicates the summary HR estimate with its 95% CI.

Back to article page